Interleukin-6 is associated with noninvasive markers of liver fibrosis in HIV-infected patients with alcohol problems

AIDS Research and Human Retroviruses

Volumn 29, Issue 8, 2013, Pages 1110-1116

  Fuster, Daniel ^a   Tsui, Judith I ^a   Cheng, Debbie M ^a,b   Quinn, Emily K ^b   Armah, Kaku A ^c   Nunes, David ^b   Freiberg, Matthew S ^d   Samet, Jeffrey H ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; LIVER ENZYME; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADULT; AGE; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; DRUG USE; ENZYME BLOOD LEVEL; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; SEX; THROMBOCYTE; VIRUS LOAD;

ADULT; ALCOHOLISM; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; LIVER; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880549832     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0348     Document Type: Article

References (44)

1. Bica I, McGovern B, Dhar R, et al.. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32(3):492-497.
2. Joshi D, O'Grady J, Dieterich D, Gazzard B, and Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet 2011;377(9772):1198-1209.
3. Sulkowski MS and Thomas DL. Hepatitis C in the HIVinfected patient. Clin Liver Dis 2003;7(1):179-194.
4. Poynard T, Mathurin P, Lai CL, et al.. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38(3):257-265.
5. Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 2007;131(11):1728-1734.
6. Bataller R and Brenner DA. Liver fibrosis. J Clin Invest 2005; 115(2):209-218.
7. Aranzabal L, Casado JL, Moya J, et al.. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005;40(4):588-593.
8. Vallet-Pichard A and Pol S. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. J Hepatol 2006;44(1 Suppl):S28-34.
9. Mehta SH, Cox A, Hoover DR, et al.. Protection against persistence of hepatitis C. Lancet 2002;359(9316):1478-1483.
10. Graham CS, Baden LR, Yu E, et al.. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection. A meta-analysis. Clin Infect Dis 2001;33(4):562-569.
11. Thein HH, Yi Q, Dore GJ, and Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy. A meta-analysis. AIDS 2008;22(15):1979- 1991.
12. Benhamou Y, Bochet M, Di Martino V, et al.. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The multivirc group. Hepatology 1999;30(4):1054-1058.
13. Neuman MG, Sha K, Esguerra R, et al.. Inflammation and repair in viral hepatitis C. Dig Dis Sci 2008;53(6):1468-1487.
14. Kim AY and Chung RT. Coinfection with HIV-1 and HCV-a one-two punch. Gastroenterology 2009;137(3):795-814.
15. Cerny A and Chisari FV. Pathogenesis of chronic hepatitis C. Immunological features of hepatic injury and viral persistence. Hepatology 1999;30(3):595-601.
16. Missale G, Bertoni R, Lamonaca V, et al.. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996;98(3):706-714.
17. Gramenzi A, Andreone P, Loggi E, et al.. Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. J Viral Hepat 2005;12(5):525-530.
18. Zekri AR, Ashour MS, Hassan A, Alam El-Din HM, El-Shehaby AM, and Abu-Shady MA. Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression. World J Gastroenterol 2005;11(42):6624-6630.
19. Napoli J, Bishop GA, McGuinness PH, Painter DM, and McCaughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996;24(4). 759-765.
20. Szabo G, Aloman C, Polyak SJ, Weinman SA, Wands J, and Zakhari S. Hepatitis C infection and alcohol use. A dangerous mix for the liver and antiviral immunity. Alcohol Clin Exp Res 2006;30(4):709-719.
21. Blackard JT and Sherman KE. HCV/HIV co-infection. Time to re-evaluate the role of HIV in the liver? J Viral Hepat 2008;15(5):323-330.
22. Tuyama AC, Hong F, Saiman Y, et al.. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression. Implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 2010;52(2):612-622.
23. Blackard JT, Welge JA, Taylor LE, et al.. HIV mono-infection is associated with FIB-4-A noninvasive index of liver fibrosis-in women. Clin Infect Dis 2011;52(5):674-680.
24. Forrester JE, Rhee MS, McGovern BH, Sterling RK, Knox TA, and Terrin N. The association of HIV viral load with indirect markers of liver injury. J Viral Hepat 2012;19(2):e202-211.
25. Sterling RK, Lissen E, Clumeck N, et al.. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43(6):1317-1325.
26. Samet JH, Cheng DM, Libman H, Nunes DP, Alperen JK, and Saitz R. Alcohol consumption and HIV disease progression. J Acquir Immune Defic Syndr 2007;46(2):194-199.
27. Samet JH, Phillips SJ, Horton NJ, Traphagen ET, and Freedberg KA. Detecting alcohol problems in HIV-infected patients. Use of the CAGE questionnaire. AIDS Res Hum Retroviruses 2004;20(2):151-155.
28. Folstein MF, Folstein SE, and McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975;12(3):189-198.
29. Smith KL, Horton NJ, Saitz R, and Samet JH. The use of the mini-mental state examination in recruitment for substance abuse research studies. Drug Alcohol Depend 2006;82(3). 231-237.
30. Walley AY, Cheng DM, Libman H, et al.. Recent drug use, homelessness and increased short-term mortality in HIVinfected persons with alcohol problems. AIDS 2008;22(3). 415-420.
31. Jacobson Brown PM and Neuman MG. Immunopathogenesis of hepatitis C viral infection. Th1/Th2 responses and the role of cytokines. Clin Biochem 2001;34(3):167-171.
32. Baron RM and Kenny DA. The moderator-mediator variable distinction in social psychological research. Conceptual, strategic, and statistical considerations. J Personality Social Psychol 1986;51(6):1173-1182.
33. Blackard JT, Kang M, St Clair JB, et al.. Viral factors associated with cytokine expression during HCV/HIV co-infection. J Interferon Cytokine Res 2007;27(4):263-269.
34. Brenchley JM, Price DA, Schacker TW, et al.. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12(12):1365-1371.
35. Balagopal A, Philp FH, Astemborski J, et al.. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008;135(1). 226-233.
36. Balagopal A, Ray SC, De Oca RM, et al.. Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. AIDS 2009; 23(18):2397-2404.
37. Chaudhry AA, Sulkowski MS, Chander G, and Moore RD. Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIVinfected clinical cohort. HIV Med 2009;10(3):133-142.
38. Di Martino V, Rufat P, Boyer N, et al.. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users. A long-term retrospective cohort study. Hepatology 2001;34(6):1193-1199.
39. Tural C, Fuster D, Tor J, et al.. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat 2003;10(2). 118-125.
40. Samet JH, Bridden C, and Freiberg MS. HIV, hepatitis C coinfection and levels of inflammatory biomarkers typically associated with CVD risk. Alcohol Clin Exp Res 2010; 34(Suppl 3):67A.
41. Fuster D, Tsui JI, Cheng DM, et al.. Impact of lifetime alcohol use on liver fibrosis in a population of HIV-infected patients with and without hepatitis C coinfection. Alcohol Clin Exp Res 2013 [Epub ahead of print]; DOI. 10.111/acer.12129.
42. Nunes D, Fleming C, Offner G, et al.. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010;105(6):1346-1353.
43. Sanvisens A, Fuster D, Serra I, et al.. Estimated liver fibrosis and its impact on all-cause mortality of HCV-monoinfected and HCV/HIV-coinfected drug users. Curr HIV Res 2011; 9(4):256-262.
44. Bambha K, Pierce C, Cox C, et al.. Assessing mortality in women with hepatitis C virus and human immunodeficiency virus using indirect markers of fibrosis. AIDS 2012; 26(5):599-607.